Biohaven Shoots For Oral CGRP Leadership As Nurtec ODT Gains Momentum

 
• By Jessica Merrill

The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.

airport runway under the sun as background
Biohaven says Nurtec ODT launch is off to a strong start • Source: Shutterstock

More from New Products

More from Scrip